Center-Authored Papers

Filters: Author is Corey, Eva  [Clear All Filters]
2008
Morrissey C, True LD, Roudier MP, Coleman IM, Hawley S, Nelson PS, Coleman R, Wang Y-C, Corey E, Lange PH et al..  2008.  Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases.. Clinical & experimental metastasis. 25(4):377-88. Abstract
2009
Koreckij TD, Trauger RJ, Montgomery RB, Pitts TEM, Coleman I, Nguyen H, Reading CL, Nelson PS, Vessella RL, Corey E.  2009.  HE3235 inhibits growth of castration-resistant prostate cancer.. Neoplasia (New York, N.Y.). 11(11):1216-25. Abstract
2010
Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, Corey E.  2010.  Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.. BMC cancer. 10:244. Abstract
Morrissey C, Lai JS, Brown LG, Wang Y-C, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E et al..  2010.  The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.. The Prostate. 70(4):412-24. Abstract
2011
Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktaş M, Hwang MS, Darling DS, Coleman IM, Nelson PS et al..  2011.  Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases.. The American journal of pathology. 179(1):400-10. Abstract
Kumar A, White TA, MacKenzie AP, Clegg N, Lee C, Dumpit RF, Coleman I, Ng SB, Salipante SJ, Rieder MJ et al..  2011.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers.. Proceedings of the National Academy of Sciences of the United States of America. 108(41):17087-92. Abstract
2013
Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT et al..  2013.  Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.. PloS one. 8(10):e78881. Abstract
Larson SR, Zhang X, Dumpit R, Coleman I, Lakely B, Roudier M, Higano CS, True LD, Lange PH, Montgomery B et al..  2013.  Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.. The Prostate. 73(9):932-40. Abstract
Ho ME, Quek S-I, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V et al..  2013.  Prostate cancer cell phenotypes based on AGR2 and CD10 expression.. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 26(6):849-859. Abstract
Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL et al..  2013.  Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.. Clinical & experimental metastasis. Abstract
2014
Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E et al..  2014.  Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.. PloS one. 9(10):e111545. Abstract
2015
Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E et al..  2015.  Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.. PloS one. 10(6):e0130565. Abstract
Zhang X, Coleman I, Brown LG, True LD, Kollath L, Lucas JM, Lam H-M, Dumpit R, Corey E, Chéry L et al..  2015.  SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
2016
Valta MP, Zhao H, Saar M, Tuomela J, Nolley R, Linxweiler J, Sandholm J, Lehtimäki J, Härkönen P, Coleman I et al..  2016.  Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer.. Clinical & experimental metastasis. 33(4):325-37. Abstract
Lam H-M, McMullin R, Nguyen H, Coleman I, Gormley M, Gulati R, Brown L, Holt S, Li W, Ricci DS et al..  2016.  Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Roudier MP, Winters BR, Coleman I, Lam H-M, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B et al..  2016.  Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.. The Prostate. 76(9):810-22. Abstract
2017
Nguyen HM, Vessella RL, Morrissey C, Brown LG, Coleman IM, Higano CS, Mostaghel EA, Zhang X, True LD, Lam H-M et al..  2017.  LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.. The Prostate. Abstract
Winters B, Brown L, Coleman I, Nguyen H, Minas TZ, Kollath L, Vasioukhin VI, Nelson P, Corey E, Üren A et al..  2017.  Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.. Anticancer research. 37(7):3385-3396. Abstract
Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S et al..  2017.  Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer.. Cell reports. 19(10):2045-2059. Abstract
Nyquist MD, Corella A, Burns J, Coleman I, Gao S, Tharakan R, Riggan L, Cai C, Corey E, Nelson PS et al..  2017.  Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.. Molecular cancer research : MCR. 15(5):521-531. Abstract
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN et al..  2017.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.. Cancer cell. 32(4):474-489.e6. Abstract
2019
Liu Y, Horn JL, Banda K, Goodman AZ, Lim Y, Jana S, Arora S, Germanos AA, Wen L, Hardin WR et al..  2019.  The androgen receptor regulates a druggable translational regulon in advanced prostate cancer.. Science translational medicine. 11(503) Abstract